Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Omeros Corporation (NASDAQ:OMER) have received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $38.00.

OMER has been the topic of a number of research reports. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. HC Wainwright decreased their price target on shares of Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. Finally, Weiss Ratings cut shares of Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd.

Insider Activity at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of Omeros stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Omeros

A number of large investors have recently added to or reduced their stakes in OMER. UBS Group AG grew its holdings in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares in the last quarter. Vanguard Group Inc. raised its stake in Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the period. State Street Corp grew its stake in Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after buying an additional 333,798 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in Omeros by 39.3% during the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after buying an additional 263,095 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Down 1.4%

Shares of NASDAQ:OMER opened at $9.28 on Friday. Omeros has a 12-month low of $3.00 and a 12-month high of $17.65. The stock has a market cap of $671.64 million, a PE ratio of 13.26 and a beta of 2.55. The business has a 50 day moving average of $11.60 and a 200-day moving average of $11.82.

Omeros (NASDAQ:OMER) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $4.19 million. Equities research analysts expect that Omeros will post -0.94 earnings per share for the current year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.